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Purpose of the study
A new 100 mg tablet formulation of ritonavir has been
developed that would not require refrigeration. This study
compared the single-dose bioavailability of the final
ritonavir 100 mg tablet formulation following a moder-
ate-fat or high-fat meal relative to that under fasting con-
ditions.
Methods
This was a single-dose, open-label, 3-period crossover
study with a randomized, crossover design. Healthy male
and female subjects (n = 27) participated in the study.
Serial blood samples were collected for 36 hours after
each dose. Ritonavir AUC from time 0 to the last measur-
able concentration (AUCt) and from time 0 to infinity
(AUCinf), maximum plasma concentration (Cmax), and
time of Cmax (Tmax) were determined using noncom-
partmental methods. The bioavailability of the tablet fol-
lowing a meal relative to the fasting condition was
assessed by the two one-sided tests procedure using 90%
confidence intervals (CI). Safety was assessed throughout
the study.
Summary of results
Table 1 presents the food effect results of the ritonavir
pharmacokinetic parameters following administration of
the ritonavir tablet.
Ritonavir Cmax and AUC were approximately 20–24%
lower when dosed following a meal compared to admin-
istration under fasting conditions. The slight difference in
Tmax is consistent with delayed gastric emptying follow-
ing a meal. Overall, the tablet formulation was generally
safe and well tolerated.
Conclusion
Overall, ritonavir pharmacokinetics after administration
of the tablet are slightly affected by meal content (with
moderate or high fat).
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Test (Meal) Reference (Fasting) Point Estimate # 90% CI
Ritonavir Dosed Under 
Moderate Fat Meal 
Condition 
(20–30% Fat, N = 26)
Moderate Fat vs. Fasting Cmax (mg/mL) 0.47 ± 0.27 0.60 ± 0.31 0.784 0.675 – 0.910
Tmax (h) 4.2 ± 1.2 3.2 ± 1.2
AUCt (mg*h/mL) 3.8 ± 2.0 4.6 ± 2.0 0.791 0.719 – 0.870
AUCinf (mg*h/mL) 3.9 ± 2.1 4.7 ± 2.0 0.798 0.726 – 0.877
Ritonavir Dosed Under 
High Fat Meal Condition 
(50% Fat, N = 25)
High Fat vs. Fasting Cmax (mg/mL) 0.44 ± 0.21 0.60 ± 0.31 0.765 0.657 – 0.892
Tmax (h) 4.8 ± 1.1 3.2 ± 1.2
AUCt (mg*h/mL) 3.5 ± 1.6 4.6 ± 2.0 0.763 0.692 – 0.841
AUCinf (mg*h/mL) 3.6 ± 1.7 4.7 ± 2.0 0.773 0.702 – 0.851
#Antilogarithm of the difference (test minus reference) of the least square means for logarithms.Page 2 of 2
(page number not for citation purposes)
